The price of Rotarix has also increased

Including Gardasil 9

The KAOG, “It is difficult to understand the reason for the impression of MSD.”

As prices have increased for cervical cancer vaccines and rotavirus vaccines that prevent neonatal enteritis, the burden on hospitals and clinics is increasing.

 

Some medical organizations are raising the issue of unilateral price hikes for global pharmaceutical companies, but there is currently no clear solution.

 

The medical staff who have to deal with the complaints of the patients are worried a lot.

 

According to the pharmaceutical industry on the 15th, from this month, MSD Korea increased its supply price by 15% for the cervical cancer prevention vaccine Gardasil 9 and 17% for the rotavirus vaccine Rotarix.

 

The information has been guided to hospitals and clinics by HK inno.N, which is in charge of MSD sales since the beginning of this year.

 

Rotarix produced by GSK is also expected to increase by 12% from May.

 

Kwang Dong, which is in charge of Rotarix, recently guided this to hospitals and clinics.

 

According to the HIRA, the currently nonreimbursement price of Gardasil 9 for hospitals and clinics is distributed between ₩107,928 and ₩202,524.

 

Gardasil 9 is a vaccine that requires a total of 3 doses to complete the vaccination, so it costs up to ₩600,000.

 

In the case of RotaTeq, the nonreimubursement price ranges from ₩48,100 to ₩130,000, which averages ₩92,473.

 

Rotarix produced by GSK is distributed at ₩63,600 to ₩150,000, which is slightly more expensive than MSD's RotaTeq.

 

The average price is ₩125,751.

 

Gardasil 9 is up 15%, RotaTeq is up 17%, and Rotarix is ​​up 12%.

 

MSD's opposition to the Gardasil 9's impression eventually came to a medical organization to seek understanding, but it is an opinion that it is difficult for medical organizations to understand pharmaceutical companies.

 

"We had a time to share the contents of the vaccine supply price increase with MSD," said Lee Ki-cheol, vice president of the Korean Association of Obstericians & Gynecologists.

 

"There are many aspects that are difficult to understand from the standpoint of the medical community.” "The supply price is quite high, with a 15% increase.

 

This is unusual and very burdensome.

 

We are going to send a letter to protest against it," he emphasized.

 

"Pharmaceutical companies say that the domestic supply price is not higher than the foreign supply price," said Ma Sang-hyuk, vice-chairman of The Korean Vaccine Society (Daegu Fatima Hospital, Pediatrics and Youth Division).

 

He said, "It is difficult to adjust the price because even if the supply price of vaccines is raised, It depends on the pharmaceutical company in the case of non-reimbursement items.

 

It is difficult to get involved legally, so it is only the doctor's role to get patient complaints." "This is because the related market operates exclusively," said Lee Ki-cheol, vice president of insurance at the KAOG.

 

"As the related supply system has been improved, policy improvements are needed to prevent this from happening again," he argued.

 

MSD believes that a price increase is inevitable because the price hikes of major non-reimbursement vaccines, including Gardasil 9, require production-specific complexity, long production periods, and quality control processes.

 

In addition, MDS explained that it is working to reduce discomfort to medical staff and patients.